- About Us
- Services & Solutions
- Novel Technology Platform
- Bioconjugation Discovery
- Bioconjugation Process Development
- Analytical Development
- Formulation and DP Development
- GMP mAb Intermediate and Conjugation Manufacturing
- GMP Formulation, Fill and Lyophilization
- Payload and Linker R&D and Manufacturing
- Ready-Made Payloads & Linkers
- WuXi XDC Singapore Site
- Investor Relations
- News & Resources
WuXi Biologics
Offering End-to-End Solutions
- About Us
About Us - Services & SolutionsAbout Us
- Investor RelationsAbout Us
- News & ResourcesAbout Us
End-to-End Solution
Antibody-oligonucleotide Conjugates (AOCs)
AOCs (antibody-oligonucleotide conjugates) are reshaping targeted RNA therapeutics. Notably, AOC is promising for rare neuromuscular disorders including DMD, oncology via oncogene silencing and immune modulation, and CNS genetic diseases with Blood-Brain Barrier penetration. As a global leading CRO and CDMO for bioconjugates, WuXi XDC leverage proprietary conjugation technology and fully integrated solutions to accelerate your AOC development programs from concept to commercial manufacturing.
AOC Service Solution
AOC Service Highlight
Integrated discovery, process development, purification and characterization capabilities complemented by scalable manufacturing facilities for end-to-end AOC development
Dedicated Oligo R&D Synthesis from mg to kg scale
Proprietary conjugation technology and extensive experience in various conjugation methods
Expertise in siRNA, ASO, PMO and CpG ODN conjugation and diverse antibody formats1000
+
AOC molecules
Delivered
Delivered
WuXiDAR1 Technology: Ideal for AOC development
WuXiDAR1™ combines the process of WuXiDAR2™ with thiol-rebridging connector to produce homogeneous DAR1 AOCs.
Advantages of WuXiDAR1 for AOC Generation
Antibody
No Engineering
Process
3 steps of reactions, No chromatography
Purity
90% of DAR1
Accessibility
No license agreement / license fee needed at discovery stage
Knowledge Center
PRESENTATION
Antibody–Oligonucleotide Conjugates Landscape and WuXi XDC’s Capabilities in AOCs
WEBINAR
From ADC to XDC: Exploring the New Wave of Bioconjugate Drugs — Antibody-Oligonucleotide Conjugates
Notice:
You are leaving WuXi Biologics Website, after which our Privacy Notice will not apply. Please keep it in mind the protection of your privacy. Are you willing to proceed?